Neurocrine Biosciences

Neurocrine Biosciences

Kevin Gorman co-founded Neurocrine Biosciences in 1992, originally built around a scientific relationship with the Salk Institute. The company went public in 1996 and spent its first two decades as a clinical-stage neuroscience developer without a commercial product. That changed in 2017 when the FDA approved INGREZZA (valbenazine), the first drug specifically indicated for tardive dyskinesia, a movement disorder caused by long-term antipsychotic use. Neurocrine now books north of $2 billion annually from INGREZZA alone, funding its pipeline entirely from operations. Neurocrine's strategy centers on discovering and developing small-molecule therapies for under-addressed neurological and endocrine conditions. Beyond INGREZZA for tardive dyskinesia and, as of 2023, Huntington's disease chorea, the commercial portfolio includes ORILISSA (elagolix) for endometriosis, which Neurocrine co-promotes with AbbVie in the US. The clinical pipeline extends into congenital adrenal hyperplasia (crinecerfont, a CRF1 antagonist), an investigational gene therapy for Parkinson's disease delivered in partnership with Voyager Therapeutics, and preclinical programs targeting schizophrenia and anxiety. Neurocrine operates primarily in the United States, with its headquarters and research labs in San Diego, California. Neurocrine employs approximately 1,400 people, with a commercial field force covering psychiatry and neurology practices nationwide. The company's discovery engine traces its origins to the lab of Dr. Wylie Vale at the Salk Institute, whose pioneering work on corticotropin-releasing factor (CRF) formed the foundation for many of Neurocrine's early programs. In 2020, Neurocrine celebrated the opening of a new 535,000-square-foot R&D campus in San Diego's University Town Center, consolidating previously scattered operations. The firm's financial independence — zero net debt as of its most recent filings — allows for a capital allocation strategy that includes a share repurchase program alongside internal pipeline investment. Neurocrine's structural differentiator is its persistence through a 25-year R&D cycle to achieve commercial profitability solely from its own internally developed molecule. While most biotechs either fail in Phase III or sell to larger pharma, Gorman built the commercial and manufacturing infrastructure to commercialize INGREZZA independently. Neurocrine now operates at a scale where it can use its cash flow to in-license or acquire mid-stage assets — most visibly the crinecerfont program acquired from Diurnal via a licensing deal — without relying on dilutive financing.